問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2025-10-01 - 2028-12-31

Phase I/II

Not yet recruiting
針對錯配修復功能(pMMR)/非微衛星高度不穩定(non-MSI-H)之局部晚期或轉移性大腸直腸癌(mCRC)患者,評估ABT301併用Tislelizumab與Bevacizumab的安全性與療效之開放性.多中心.第一/二期臨床試驗

  • Condition/Disease

    第 1 部分：*評估在 pMMR/non-MSI-H 大腸直腸癌患者中，遞增劑量的 ABT-301 與固定劑量的 Tislelizumab（200 mg，靜脈輸注）和 Bevacizumab（7.5 mg/kg，靜脈輸注，每 3 週一次）合併使用時的安全性及耐受性。*確定 ABT-301 的最大耐受劑量 (MTD) 並選擇其建議的第二期劑量 (RP2D)。第 2 部分：*評估兩種劑量/方案的 ABT-301 與 Tislelizumab 和 Bevacizumab 合併使用的療效。

  • Test Drug

    膠囊劑 靜脈輸注液 靜脈輸注液

Participate Sites
7Sites

Recruiting7Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2021-08-01 - 2026-03-31

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-07-27 - 2026-09-30

Phase II

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
13Sites

Recruiting13Sites

2023-10-16 - 2027-06-30

Phase III

Completed
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-3)

  • Condition/Disease

    severe eosinophilic asthma (EXHALE-3)

  • Test Drug

    tablets

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2025-12-31

Phase III

Completed
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)

  • Condition/Disease

    eosinophilic asthma (EXHALE-4)

  • Test Drug

    tabltes

Participate Sites
9Sites

Recruiting9Sites

2025-06-01 - 2028-07-31

Phase III

Completed
An Open-Label Long-Term Phase III Extension Study to Assess the Long-Term Safety and Tolerability of Dexpramipexole in Participants with Severe Eosinophilic Asthma (EXHALE-5)

  • Condition/Disease

    Severe Eosinophilic Asthma

  • Test Drug

    tablet

Participate Sites
3Sites

Recruiting3Sites

2005-10-01 - 2007-09-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-01-04 - 2025-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2023-06-16 - 2024-05-15

Phase III

Completed
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

  • Condition/Disease

    Obesity、 Overweight、 Knee Pain Chronic、 Knee Osteoarthritis、 Obstructive Sleep Apnea

  • Test Drug

    LY3437943

Participate Sites
4Sites

Recruiting4Sites

1 50 51 52 53 54 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB